Trial Profile
The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Flutemetamol-F-18 (Primary) ; RO 6958948 (Primary)
- Indications Alzheimer's disease; Cognition disorders; Neurodegenerative disorders
- Focus Biomarker; Diagnostic use
- Acronyms BioFINDER2
- 04 Dec 2023 Results (n=912) assessing plasma biomarkers for identifying Ab positivity and stage of tau accumulation published in the JAMA Neurology
- 20 Jul 2023 Results using BioFINDER-2 data investigating whether CU individuals who are Ab-negative and tau-PET positive in the medial temporal lobe show cognitive decline and increases in CSF phosphorylated tau (P-tau) or tau PET over time, presented at the Alzheimer's Association International Conference 2023
- 20 Jul 2023 Results (n=231) assessing longitudinal changes in tau accumulation associated with elevated CSF p-tau and tau-PET biomarkers presented at the Alzheimer's Association International Conference 2023